MedTrace Logo

Molecular and Functional Imaging in SNCA, Parkin and PINK1

NCT04084509 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-04-06

No results posted yet for this study

Summary

Parkinson's Disease (PD) is a progressive neurodegenerative disease characterized clinically by bradykinesia, resting tremor, rigidity, and postural instability. The hallmark pathophysiological alteration is a loss of dopaminergic transmission across the nigrostriatal pathway. According to Braak's neuropathological staging of disease, the pathological process in PD occurs in a gradual ascending fashion, starting from the olfactory bulb and progressing to the brainstem, with preferential involvement of the raphe nuclei, which contain serotonergic nuclei, and the noradrenergic locus coeruleus, before involving the substantia nigra and thereafter the whole brain. Little is known about the mechanisms underlying neuronal degeneration in PD and currently, no treatment is available to halt disease progression in PD. The pathophysiological characterisation of phenomena occurring in the time window between the pathological start of the disease and the onset of motor symptoms is crucial to develop potential neuroprotective agents. Several genes causing, the so-called monogenic parkinsonism, have been discovered providing important insights on the pathogenesis of PD.

The objective of the study is to characterize the molecular phenomena underlying genetic forms of parkinsonism and, therefore, providing further insights about the possible mechanisms taking place in PD and help identify targets for disease-modifying therapeutics, by using PET imaging with \[11C\]DASB (a marker of Serotonin transporter), SPECT imaging using \[123I\]FP-CIT (a marker of the presynaptic Dopamine transporter), and multi-modal MRI imaging, clinical markers (motor and non-motor symptoms and neuropsychological battery), blood and CSF biomarkers.

Conditions

  • Parkinson Disease
  • PARK1
  • PARK2

Sponsors & Collaborators

  • King's College Hospital NHS Trust

    collaborator OTHER

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • King's College London

    lead OTHER

Principal Investigators

  • Marios Politis, MD MSc PhD · King's College London

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-09-30
Completion
2022-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04084509 on ClinicalTrials.gov